News - Shionogi


Current filters:


Popular Filters

9 to 33 of 33 results

Clinical updates at ROI meeting on GSK's dolutegravir and Medivir's simeprevir


UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drug major Shionogi (TYO: 4507) reported interim…


FDA approves Shionogi's Osphena for postmenopausal women experiencing pain during sex


The US Food and Drug Administration yesterday approved Japanese drug major Shionogi's (TYO: 4507) Osphena…

North AmericaospemifeneOsphenaPharmaceuticalQuatRx PharmaRegulationShionogiWomen's Health

Takeda, Shionogi, Ono Pharma and Mitsubishi Tanabe post nine-month results


Takeda Pharmaceuticals (TYO: 4502), Japan's largest drugmaker, has reported nine-month 2013 results with…

FinancialMitsubishi TanabeOno PharmaceuticalPharmaceuticalShionogiTakeda Pharmaceuticals

ViiV Healthcare's dolutegravir shows promise in hard-to-treat HIV patients


ViiV Healthcare, and HIV/AIDS company jointly owned by GlaxoSmithKline (LSE: GSK), Pfizer (NYSE: PFE)…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Revised terms for ViiV Healthcare and Shionogi HIV partnership


UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

Mylan in patent settlement with Shionogi over Orapred ODT


US generic drugs major Mylan (Nasdaq: MYL) has entered into a patent settlement with Japan's Shionogi…

CIMA LabsGenericsLegalMylan LaboratoriesNorth AmericaOrapred ODTPatentsRespiratory and PulmonaryShionogi

Shionogi partner Ildong gains South Korean approval for Pirespa


Japanese drug major Shionogi (TYO: 4507) says that its South Korean partner Ildong Pharma has received…

Asia-PacificIldong PharmaPharmaceuticalPirespapirfenidoneRegulationRespiratory and PulmonaryShionogi

Japanese filings for Shionogi's metreleptin and Otsuka's tolvaptin


Japanese drugmaker Shionogi (TYO: 4507) said last week that it has filed a New Drug Application with…

Asia-PacificmetreleptinNephrology and HepatologyOtsukaPharmaceuticalRare diseasesRegulationSamscaShionogitolvaptin

Arzerra and ospemifene NDAs submitted in Japan


UK pharma giant GlaxoSmithKline (LSE: GSK) and Danish company Genmab A/S (OMX: GEN) have submitted a…

ArzerraAsia-PacificGenmabGlaxoSmithKlineOncologyospemifenePharmaceuticalQuatRx PharmaRegulationShionogiWomen's Health

ViiV and Shionogi say dolutegravir meets primary endpoint in HIV


ViiV Healthcare, the HIV/AIDS joint venture of UK drugs giant GlaxoSmithKline (LSE: GSK) and US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Shionogi sets up new EU unit; posts 37% profit hike


Japanese drug major Shionogi (TYO: 4507) yesterday revealed that it has decided to establish its 100%…


Shire and Shionogi to jointly develop and commercialize ADHD drugs in Japan


Ireland-headquartered drugmaker Shire (LSE: SHP) has entered into an agreement with Japan’s Shionogi…

Asia-PacificLicensingMarkets & MarketingNeurologicalPharmaceuticalShionogiShire

Disappointing first-half FY 2011/12 results from Japanese drugmakers


There was a slew of financial results for the first half of fiscal year 2011 (to September 30, 2011)…

Daiichi SankyoDainippon Sumitomo PharmaFinancialMitsubishi TanabeNippon ChemipharPharmaceuticalShionogi

Lupin debuts generics of two Watson drugs, NOR-QD and Fortamet, in USA


Indian drugmaker Lupin (500257. BY) last week revealed that it had launched generic versions in the USA…

DiabetesFortametGenericsLupinMarkets & MarketingNor-QDNorth AmericaPatentsReproductiveShionogiWatson Pharmaceuticals

Shionogi completes new $247 million research facility


Japanese drug major Shionogi (TKO: 4507)last week held an inauguration ceremony of the new pharmaceutical…


Shionogi makes $185 million offer for China’s C&O Pharma; reports first-quarter results


Japanese drug major Shionogi (TKO: 4507) says it has signed an agreement to acquire the Chinese drugmaker…

Asia-PacificC&O PharmaFinancialMergers & AcquisitionsPharmaceuticalShionogi

Shionogi pays Victory Pharma $118 million for nine drugs


The US subsidiary of Japanese drug major Shionogi (TKO: 4507) has entered into an agreement to acquire…

Antibiotics and Infectious diseasesMergers & AcquisitionsNaprelanNeurologicalNorth AmericaPharmaceuticalShionogiVictory Pharma

Sandoz expands strategic alliance with Nipro in Japan; Shionogi licenses drug to Ildong


Sandoz, a generics subsidiary of US drug major Novartis (NOVN: VX) has entered into a strategic alliance…

Asia-PacificGenericsIldong PharmaLicensingNovartisPharmaceuticalpirfenidoneSandozShionogi

Shionogi posts strong fiscal year 2011 results; shows efficacy of Kapvay ER


Japanese drug major Shionogi (TKO: 4507) reported its unconsolidated fiscal year 2011 (ended March) results…


9 to 33 of 33 results

Back to top